William Blair Has Negative Forecast for SERA Q3 Earnings

Sera Prognostics, Inc. (NASDAQ:SERA) – Equities researchers at William Blair reduced their Q3 2025 earnings estimates for Sera Prognostics in a research report issued on Monday, February 3rd. William Blair analyst A. Brackmann now expects that the company will post earnings per share of ($0.24) for the quarter, down from their prior estimate of ($0.23). The consensus estimate for Sera Prognostics’ current full-year earnings is ($0.96) per share. William Blair also issued estimates for Sera Prognostics’ Q4 2025 earnings at ($0.24) EPS and FY2025 earnings at ($0.98) EPS.

Sera Prognostics (NASDAQ:SERA) last issued its earnings results on Wednesday, November 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The firm had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.09 million. During the same quarter in the previous year, the company posted ($0.23) EPS.

Sera Prognostics Price Performance

Shares of NASDAQ:SERA opened at $4.71 on Wednesday. The stock’s fifty day moving average price is $7.24 and its 200-day moving average price is $7.28. The company has a market cap of $159.06 million, a P/E ratio of -4.76 and a beta of 0.81. Sera Prognostics has a 1 year low of $4.61 and a 1 year high of $12.35.

Insider Activity

In other Sera Prognostics news, insider Paul Kearney sold 4,078 shares of the stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $7.32, for a total value of $29,850.96. Following the transaction, the insider now directly owns 176,889 shares in the company, valued at approximately $1,294,827.48. This trade represents a 2.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel Benjamin Jackson sold 4,727 shares of the business’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $7.32, for a total transaction of $34,601.64. Following the sale, the general counsel now directly owns 135,528 shares of the company’s stock, valued at approximately $992,064.96. The trade was a 3.37 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 93,215 shares of company stock valued at $666,835 over the last three months. Insiders own 15.80% of the company’s stock.

Institutional Trading of Sera Prognostics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC bought a new position in shares of Sera Prognostics during the 2nd quarter valued at approximately $162,000. The Manufacturers Life Insurance Company purchased a new position in Sera Prognostics during the second quarter valued at approximately $68,000. SG Americas Securities LLC bought a new position in shares of Sera Prognostics in the third quarter worth approximately $78,000. Prime Capital Investment Advisors LLC purchased a new stake in shares of Sera Prognostics in the third quarter worth $104,000. Finally, Quest Partners LLC lifted its position in shares of Sera Prognostics by 533.5% in the third quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock valued at $50,000 after acquiring an additional 5,415 shares in the last quarter. Hedge funds and other institutional investors own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.